Država: Južnoafrička Republika
Jezik: engleski
Izvor: South African Health Products Regulatory Authority (SAHPRA)
Alcon
ALOMIDE ™ ophthalmic solution SCHEDULING STATUS: S1 PROPRIETARY NAME (and dosage form): ALOMIDE ™ ophthalmic solution COMPOSITION: ALOMIDE contains 1,78 mg lodoxamide tromethamine equivalent to 1 mg lodoxamide per mL and 0,007% (m/v) benzalkonium chloride as preservative in a sterile, buffered isotonic solution. PHARMACOLOGICAL CLASSIFICATION: A.15.4 Ophthalmic preparations, other. PHARMACOLOGICAL ACTION: Lodoxamide is a mast cell stabilizer. In vitro it inhibits the type I immediate hypersensitivity reaction, preventing the antigen specific induced release of histamine and other mast cell inflammatory mediators by preventing the movement of calcium into the mast cell after stimulation. Lodoxamide has no intrinsic vasoconstrictor, antihistaminic, cyclo- oxygenase inhibition or other anti-inflammatory activity. INDICATIONS: ALOMIDE is indicated in the treatment of non-infectious allergic conjunctivitis (allergic/atopic conjunctivitis, vernal conjunctivitis, giant papillary conjunctivitis) in which type I immediate hypersensitivity is a major factor. The aetiologic factors are unknown, but common airborne allergens and contact lenses have been implicated. CONTRA-INDICATIONS: Hypersensitivity to any component of the medicament. Safety in pregnancy and lactation and safety and effectiveness in children below the age of four years has not been established. WARNINGS: ALOMIDE is not intended for injection. As with all preparations containing benzalkonium chloride, users of soft (hydrophilic) contact lenses should refrain from wearing lenses while under treatment with ALOMIDE. Lenses may be worn within a few hours of discontinuation of treatment. The recommended frequency of administration should not be exceeded. As the possibility of adverse effects on the corneal permeability and the danger of disrupt Pročitajte cijeli dokument